Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Saeed O, Panarelli N, Umrau K, Lee H, Westerhoff M, Cheng J, et al. The Histopathologic Features of Sickle Cell Hepatopathy: A Multi-Institutional Study. Am J Clin Pathol. 2022;157(1):73-81.

Feng H, Jiang B, Xing W, Sun J, Greenblatt MB, Zou W. Skeletal stem cells: origins, definitions, and functions in bone development and disease. Life Med. 2022;1(3):276-293.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Casa D, Sung S, Mosquera JM, Rao R. Fine-needle aspiration biopsy of growing teratoma syndrome as a diagnostic pitfall of metastatic adenocarcinoma. Diagn Cytopathol. 2022;50(2):E71-E75.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Cao XE, Ongagna-Yhombi SY, Wang R, Ren Y, Srinivasan B, Hayden JA, et al. A diagnostic platform for rapid, simultaneous quantification of procalcitonin and C-reactive protein in human serum. EBioMedicine. 2022;76:103867.

Rosen DB, Murphy EA, Gejman RS, Capili A, Friedlander RL, Rand S, et al. Cytokine response over the course of COVID-19 infection in pregnant women. Cytokine. 2022;154:155894.

Solomon JP, Yang S-, Choudhury NJ, Ptashkin RN, Eslamdoost N, Falcon CJ, et al. Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors. Clin Cancer Res. 2022;28(21):4649-4659.

Smithgall MC, Murphy EA, Schatz-Siemers N, Matrai C, Tu J, Baergen RN, et al. Placental pathology in women vaccinated and unvaccinated against SARS-CoV-2. Am J Obstet Gynecol. 2022;227(5):782-784.

Nuzzo PV, Adib E, Weise N, Curran C, Stewart T, Freeman D, et al. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clin Genitourin Cancer. 2022;20(4):301-306.